Susquehanna initiates coverage on Array BioPharma (Nasdaq: ARRY) with a Positive. Price target $10.

Susquehanna analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE